Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of UCB4940 Administered as Add-on to Certolizumab Pegol Therapy in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Trial Profile

A Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of UCB4940 Administered as Add-on to Certolizumab Pegol Therapy in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary) ; Certolizumab pegol
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 18 Jun 2019 Georgia was a planned location as per European Clinical Trials Database.
    • 08 Jun 2019 Primary endpoint has been met. (Change from Baseline 2 in DAS28(CRP)), as per results published in the Annals of the Rheumatic Diseases.
    • 08 Jun 2019 Results evlatuating the safety and efficacy of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis and inadequate response (IR) to certolizumab pegol are published in the Annals of the Rheumatic Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top